The combination of bevacizumab/Avastin and erlotinib/Tarceva is relevant for the treatment of metastatic renal cell carcinoma: the role of a synonymous mutation of the EGFR receptor

Metastatic clear cell renal cell carcinomas (mRCC) over-express the vascular endothelial growth factor (VEGF). Hence, the anti-VEGF antibody bevacizumab/Avastin (BVZ) combined with interferon alpha (IFN) was approved for the treatment of mRCC. However, approval was lost in July 2016 due to the absen...

Descripción completa

Detalles Bibliográficos
Autores principales: Grépin, Renaud, Guyot, Mélanie, Dumond, Aurore, Durivault, Jérôme, Ambrosetti, Damien, Roussel, Jean-François, Dupré, Florence, Quintens, Hervé, Pagès, Gilles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6956821/
https://www.ncbi.nlm.nih.gov/pubmed/31938054
http://dx.doi.org/10.7150/thno.38346

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6956821/
https://www.ncbi.nlm.nih.gov/pubmed/31938054
http://dx.doi.org/10.7150/thno.38346

Ejemplares similares